Table 2.

Summary of permitted and prohibited concomitant medications

Permitted medications

Prohibited medications

Stable doses of azathioprine (if receiving for ≥12 months prior to baseline) Azathioprine should be continued at the same dosage during study treatment Stable doses of corticosteroids (prednisolone or equivalent) ≤20 mg/d or equivalent in patients with prior corticosteroid therapy Paracetamol as needed for mild pain

Any other blood or plasma‐derived products (except for emergency reasons) Patients who receive immunoglobulin preparations other than panzyga will be withdrawn from the study Corticosteroids (prednisolone or equivalent) > 20 mg/d or equivalent Plasma exchange Ciclosporin, methotrexate, mitoxantrone, mycophenolate mofetil, interferon or other immunosuppressive or immunomodulatory drugs Rituximab, alemtuzumab, cyclophosphamide, or other chemotherapeutic regimens Any experimental treatment Routine pre‐medication to alleviate potential tolerability issuesa

^aPatients who experience 2 consecutive infusion‐related adverse events may receive pre‐medication with antipyretics, antihistamines, or antiemetic agents.